Ivermectin and gynecologic cancer: What’s the data?

Highlights

•

Ivermectin is currently approved by the US Food and Drug Administration (FDA) in 1996 as an oral medication for intestinal strongyloidiasis and onchocerciasis.

•

The data on ivermectin as a gynecologic cancer-fighting compound is lacking.

•

Clinical studies on ivermectin use in cancer are limited to effects observed in cell lines.

•

We have not assessed ivermectin’s safety and efficacy in gynecologic cancers.

•

We do not recommend and strongly caution the use of ivermectin in the treatment of gynecologic cancers.